Printer Friendly
The Free Library
19,585,763 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Biomet announces record fiscal year results and cash dividend.


WARSAW, Ind.--(BW HealthWire)--July 2, 1997--(NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:BMET BMET Biomedical Engineering Technology
BMet Bachelor of Metallurgy
BMET Bio-Medical Equipment Repair Technician
)

Biomet, Inc. today reported record sales and earnings for its fiscal year and fourth quarter ended May 31, 1997. -0-
                   ($000's Except Per Share Data)

Fiscal Year Ended May 31:
                             1997          1996     Percent Change
Net sales                  $580,347      $535,159          8 %
Gross profit                394,552       360,795          9
Operating income            159,811       137,280         16
Net income                  106,454        94,106(a)      13
Earnings per share              .94           .82(a)      15

U.S. sales                 $425,522      $396,707          7 %
Foreign sales               154,825       138,452         12

Reconstructive sales       $352,122      $326,834          8 %
EBI sales                   114,321       108,627          5
Other products              113,904        99,698         14


Fourth Quarter Ended May 31:
                             1997          1996     Percent Change
Net sales                  $152,996      $141,417          8 %
Gross profit                104,893        95,755         10
Operating income             42,959        37,990         13
Net income                   28,903        27,129(a)       7
Earnings per share              .26           .24(a)       8

U.S. sales                 $111,116      $101,232         10 %
Foreign sales                41,880        40,185          4

Reconstructive sales       $ 94,634      $ 88,763          7 %
EBI sales                    29,001        27,617          5
Other products               29,361        25,037         17

(a) Includes approximately $1.7 million and 1.5 cents per share in
non-recurring net income as a result of a one time payment from
United States Surgical Corporation (USSC) surrounding the termination
of a joint venture agreement between Biomet and USSC.




Increases in sales and earnings for fiscal year 1997 as compared to fiscal year 1996 were principally attributed to the continued market penetration Noun 1. market penetration - the extent to which a product is recognized and bought by customers in a particular market
penetration - the act of entering into or through something; "the penetration of upper management by women"
 of the Company's reconstructive devices in both the international and domestic markets. Biomet's Maxim Total Knee and Alliance Hip Systems continued to capture market share in the domestic reconstructive market. In addition, the Company is experiencing strong sales increases in the internal fixation internal fixation
n.
The stabilization of fractured bony parts by direct fixation to one another with surgical wires, screws, pins, or plates.
 market. EBI's growth was due to increased sales of the SpF Spinal Fusion spinal fusion
n.
A surgical procedure in which vertebrae are joined. Also called spondylosyndesis.


Spinal fusion 
 Stimulation System and the EBIce Controlled Cold Therapy System. The reported earnings for the fourth quarter and the fiscal year do not reflect any additional provision for liabilities that ultimately may be incurred with respect to the previously announced jury verdict of approximately $149 million against the Company in the Orthofix litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute.

When a person begins a civil lawsuit, the person enters into a process called litigation.
.

Biomet, Inc. also announced that the Board of Directors of the Company has declared a cash dividend of eleven cents ($.11) per share, payable August 8, 1997 to shareholders of record at the close of business on July 11, 1997. Dane A. Miller, Ph.D., President and Chief Executive Officer of Biomet, said "The declaration of this dividend is an expression of appreciation for the continued support of our shareholders and reflects the Board's confidence and optimism in Biomet's operational direction."

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by orthopedic medical specialists in both surgical and non-surgical therapy, including reconstructive and trauma devices, electrical bone growth stimulators, orthopedic support devices, operating room operating room
n. Abbr. OR
A room equipped for performing surgical operations.
 supplies, spinal implants, general surgical instruments A surgical instrument is a specially designed tool or device for performing specific actions of carrying out desired effects during a surgery or operation, such as modifying biological tissue, or to provide access or viewing it. , arthroscopy Arthroscopy Definition

Arthroscopy is the examination of a joint, specifically, the inside structures. The procedure is performed by inserting a specifically designed illuminated device into the joint through a small incision.
 products and craniomaxillofacial implants and instruments. Headquartered in Warsaw, Indiana Warsaw is a city in, and the county seat of, Kosciusko County, Indiana, United StatesGR6. The population was 12,415, as of the 2000 census.

Cradled between Winona Lake, Pike Lake and Center Lake, Warsaw is nicknamed "Lake City
, Biomet and its subsidiaries currently distribute products in approximately 100 countries.

For further information contact Greg W. Sasso, Vice President, Corporate Development and Communications, or Sheila Warren, Manager, Corporate Communications Corporate communications is the process of facilitating information and knowledge exchanges with internal and key external groups and individuals that have a direct relationship with an enterprise.  at (219) 267-6639.

CONTACT: Biomet, Inc.

Greg W. Sasso or Sheila Warren, 219/267-6639
COPYRIGHT 1997 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 2, 1997
Words:547
Previous Article:Intersphere Inks Jeremy's Cookies & Creams Ad & PR Deal.
Next Article:Inacom Corp. Designated Compaq National Systems Service Provider.
Topics:



Related Articles
Biomet announces second quarter and first half results.
Biomet announces third quarter and nine month results.
Biomet Announces Record First Quarter Results.
Biomet Announces Record Third Quarter and Nine Month Results.
Biomet Announces Record Fiscal Year Results and Cash Dividend.
Biomet Announces Appellate Court Reduction of Orthofix Award.
Biomet Announces Record Fourth Quarter and Fiscal Year End Results, Cash Dividend and Expansion of Its Share Repurchase Program.
Biomet Announces Record Fourth Quarter and Fiscal Year-End Results, Cash Dividend and Expansion of Its Share Repurchase Program.
Biomet Announces Fourth Quarter and Fiscal Year-End Results, and Cash Dividend.
Biomet, Inc. Announces Update on Review of Historical Stock Option Granting Practices.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles